EGFR and non-small cell lung carcinoma: The significantly superior progression-free survival (PFS) benefit of dacomitinib over gefitinib in the ARCHER 1050 trial provided the basis for its use as a standard first-line option in EGFR-positive advanced NSCLC (Wu et al., 2017).